Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
18.61
+0.05 (0.27%)
At close: May 12, 2025, 4:00 PM
18.27
-0.34 (-1.83%)
After-hours: May 12, 2025, 6:22 PM EDT
Innoviva Employees
Innoviva had 127 employees as of December 31, 2024. The number of employees increased by 15 or 13.39% compared to the previous year.
Employees
127
Change (1Y)
15
Growth (1Y)
13.39%
Revenue / Employee
$2,912,157
Profits / Employee
-$470,268
Market Cap
1.17B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INVA News
- 5 days ago - Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress - Business Wire
- 2 months ago - Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - PRNewsWire
- 2 months ago - Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference - Business Wire
- 2 months ago - Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress - Business Wire
- 2 months ago - Innoviva: Underappreciated Strength In Hospital Therapeutics - Seeking Alpha
- 3 months ago - Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 5 months ago - Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole) - Business Wire
- 5 months ago - Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States - GlobeNewsWire